As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
Latest Information Update: 16 Jun 2022
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 13 Jun 2022 Planned End Date changed from 1 Jan 2023 to 1 Dec 2024.
- 13 Jun 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2023.
- 13 Jun 2022 Planned initiation date changed from 1 Jan 2021 to 1 Oct 2022.